A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma

Area of Science:

• Immunology
• Pharmacology
• Genetics

Background:

• Cysteinyl leukotrienes (CYSLTR) are key mediators in asthma pathophysiology.
• Current asthma therapies target CYSLTR1, but CYSLTR2's role remains less understood.
• This study explores CYSLTR2's involvement in asthma through genetic and pharmacological analysis.

Purpose of the Study:

• To investigate the genetic association between CYSLTR2 polymorphisms and asthma.
• To characterize the pharmacological differences of a specific CYSLTR2 coding variant.
• To assess the potential of CYSLTR2 modulation as an asthma therapeutic strategy.

Main Methods:

• Transmission disequilibrium test (TDT) was used to assess CYSLTR2 polymorphism association with asthma in two independent family cohorts.
• A coding polymorphism (601A>G) in CYSLTR2 was identified and analyzed.
• Calcium mobilization assays were performed to compare the potency of cysteinyl leukotrienes on wild-type and variant CYSLTR2.

Main Results:

• A significant association was found between the CYSLTR2 601A>G polymorphism and asthma (P = 0.003, replicated P = 0.04).
• The G allele of the 601A>G variant was under-transmitted in asthmatic individuals, suggesting a protective role.
• The 601A>G variant showed reduced potency (approximately five-fold) for LTD4 compared to wild-type CYSLTR2, while LTC4 and LTE4 potencies were similar.

Conclusions:

• The CYSLTR2 601A>G variant is associated with resistance to asthma.
• This variant alters LTD4 binding potency.
• Targeting CYSLTR2 presents a potential novel therapeutic avenue for asthma pharmacotherapy.